Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades
Rhea-AI Filing Summary
Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments II, L.P. updated their ownership report for Shattuck Labs, Inc. common stock. They may be deemed to beneficially own 10,019,421 shares, representing 9.9% of the class, with shared voting and dispositive power over all of these shares. Redmile Biopharma Investments II, L.P. is reported with 8,125,342 shares, or 8.1% of the class.
The position as of July 17, 2026 comprises 5,233,076 shares of common stock (including 3,338,997 shares held directly by RBI II) plus 4,786,345 shares issuable upon exercise of pre-funded warrants, the maximum permitted under a 9.99% Beneficial Ownership Limitation. The Redmile funds hold pre-funded warrants for up to 10,943,951 shares, including 5,647,258 underlying shares at RBI II, and 146,086 shares subject to stock options exercisable within 60 days that are held by a former director as nominee for Redmile. Between July 10 and July 17, 2026, the group executed multiple open market sales and on July 17 used approximately $1,000,000 of working capital to purchase 143,808 shares at a weighted average price of about $7.46 per share.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Beneficial Ownership Limitation regulatory
pre-funded warrants financial
open market transactions financial
working capital financial
underwritten offering financial
beneficially owned regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.